Pharmaceutical intermediates
Calcitriol Intermediates
5 pharmaceutical intermediates for Calcitriol. Indication: Psoriasis; Postmenopausal osteoporosis; Renal insufficiency; Vitamin D deficiency.
About Calcitriol
- Originator
- Validus
- Indication
- Psoriasis; Postmenopausal osteoporosis; Renal insufficiency; Vitamin D deficiency
- Approved Date
- 08/17/1978
Available intermediates
5 intermediates currently listed for Calcitriol. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| Silane, [[(1a,3b,5E,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraene-1,3-diyl]bis(oxy)]bis[(1,1-dimethylethyl)dimethyl- (9CI) | 111594-58-2 | / | / |
| (S)-2-((1R,3aS,7aR,E)-4-((E)-2-((3S,5R)-3,5-bis(tert-butyldiMethylsilyloxy)-2-Methylenecyclohexylidene)ethylidene)-7a-Methyloctahydro-1H-inden-1-yl)propan-1-ol | 128387-35-9 | / | / |
| (5R)-ethyl 5-((1R,3aS,7aR)-4-((E)-2-((3S,5R)-3,5-bis(tert-butyldiMethylsilyloxy)-2-Methylenecyclohexylidene)ethyl)-7a-Methyloctahydro-1H-inden-1-yl)hexanoate | 169900-32-7 | / | / |
| 5-{2-[1-(5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol | 73837-24-8 | / | / |
| 6-(4-{2-[3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohexylidene]-ethylidene}-7a-methyl-octahydro-inden-1-yl)-2-methyl-heptan-2-ol | 140710-96-9 | / | / |
Building toward Calcitriol?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →